[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Connecticut\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":372},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,80,107,145,172,206,227,254,276,297,322,347],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100490700","phase-4-optimizing-evidence-based-hiv-prevention-targeting-people-who-inject-drugs-on-prep-100490700",false,"NCT05669534","Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP","MOST","Inclusion Criteria:\n\n* being 18 years or older\n* meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone, buprenorphine) at the APT Foundation, Inc.\n* showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening\n* having initiated Pre-Exposure Prophylaxis (PrEP) within the past week\n* confirming HIV-negative status through proof of PrEP prescription\n* reporting unsafe injection drug use practices or unprotected sex within the past 3 months\n* having a cell phone\n* being able to read and understand in English\n\nExclusion Criteria:\n\n* unable to provide consent\n* actively suicidal\n* actively homicidal\n* actively psychotic\n* display MoCA scores suggestive of dementia","ALL","18 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).",[26,27],"Hiv","Opioid Use Disorder",[29,30,31,32,33,34,35],"people who inject drugs","HIV","cognitive dysfunction","pre-exposure prophylaxis","multiphase optimization strategy","medication for opioid use disorder","opioid use disorder","RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2023-03-01",{"date":44,"type":20},"2027-01-01",{"name":46,"class":47},"University of Connecticut","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100639240","effect-of-a-telephone-reminiscence-intervention-on-mental-health-100639240","NCT07576855","Effect of a Telephone Reminiscence Intervention on Mental Health","Strengthening Bonds: A Telephone Reminiscence Intervention to Reduce Social Isolation and Improve Mental Health in Rural Older Adults","TRIM","Inclusion Criteria:\n\n* Older adults aged 60 years or older living in a rural area.\n* Able to read and speak English.\n* Living in a rural area as defined by the U.S. Census Bureau.\n* Has an informal caregiver (family member, partner, friend, or neighbor) willing to participate, or is an informal caregiver of an eligible older adult.\n* Able to participate in telephone-based activities.\n\nExclusion Criteria:\n\n* Significant hearing impairment that would interfere with telephone participation.\n* Cognitive impairment as indicated by three or more errors on a brief cognitive screening assessment.\n* Participation in the program development phase of this study.",true,"60 Years",{"count":60,"type":20},170,[62],"NA","The goal of this study is to learn whether a telephone-based program that helps people share life memories can reduce loneliness and improve mental well-being, life satisfaction, and social support in older adults and their caregivers living in rural areas.\n\nThis study has two parts. In the first part, researchers will gather feedback from a small group of older adults and informal caregivers to see if the updated telephone reminiscence program works well and is easy to use.\n\nIn the second part, researchers will test the telephone reminiscence program in a clinical trial study to see whether the updated telephone reminiscence program reduces loneliness and improves social support, life satisfaction, and mental well-being in older adults and their caregivers. The researchers will also examine how the program impacts how often and for what reason you reminisce.\n\nThe main questions this study aims to answer are:\n\n* Does the telephone reminiscence program improve social support, life satisfaction, and mental well-being and reduce loneliness in rural older adults and their caregivers? How does the telephone reminiscence impact how often and for what reason participants reminisce?\n* How often and how long do participants use the program?\n* How satisfied are older adults and informal caregivers with the program? In this study researchers will compare participants who begin the telephone reminiscence program right away with participants who start the program after a 12-week waiting period to see whether starting the program earlier leads to better outcomes.\n\nParticipants will:\n\n* Take part in telephone calls 3 times a week that invite older adults to talk about their life experiences.\n* Answer brief survey questions about social support, loneliness, and mental well-being, and life satisfaction over time.\n* Include both older adults and their informal caregivers, who may also participate by recording questions in their own voice.",[65],"Mental Health",[67,68,69,70],"Older Adults","Telephone-Based Intervention","Reminiscence","Mental Well-Being","NOT_YET_RECRUITING","2026-05-04",{"date":74,"type":40},"2026-05-08",{"date":76,"type":20},"2026-08-20",{"date":78,"type":20},"2027-06",{"name":46,"class":47},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100461034","early-phase-1-cannabidiol-effects-on-learning-and-anxiety-100461034","NCT05283382","Cannabidiol Effects on Learning and Anxiety","Inclusion Criteria:\n\n* 18-50 years of age\n\nExclusion Criteria:\n\n1. Difficulties seeing a computer screen\n2. Anyone currently taking CBD within the last 24 hours.\n3. Anyone using any cannabis product within the last 24 hours.\n4. Heart problems or heart disease\n5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm\n6. Are currently pregnant or breast-feeding","50 Years",{"count":88,"type":20},160,[90],"EARLY_PHASE1","To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.",[93],"Anxiety and Fear",[95,96,97,98],"social anxiety","fear conditioning","cannabidiol","electrodermal response","2026-04-23",{"date":101,"type":40},"2026-04-29",{"date":103,"type":40},"2024-10-30",{"date":105,"type":20},"2027-02",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100611282","a-novel-digital-tool-physicians-can-use-to-prescribe-exercise-to-patients-with-cardiovascular-disease-risk-factors-100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.","64 Years",{"count":117,"type":20},72,[62],"The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[121,122,123,124,125],"Hypertension","Dyslipidemia","Diabetes Mellitus","Obesity","Cardiovascular Disease",[127,128,129,130,131,132,133,134,135],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Precision Medicine","Primary Health Care","2026-04-14",{"date":138,"type":40},"2026-04-15",{"date":140,"type":40},"2026-03-30",{"date":142,"type":20},"2026-05-31",{"name":46,"class":47},3,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":57,"sex":153,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":48},"100577172","jomcare-study---a-harm-reduction-study-100577172","NCT06794840","JomCare Study - A Harm Reduction Study","Optimizing a Just-in-Time Adaptive Intervention to Increase Uptake of Chemsex Harm Reduction Services in MSM: A Micro-randomized Trial","JomCare","Inclusion Criteria:\n\n* Age ≥18 years;\n* Cisgender man;\n* HIV-negative or HIV status unknown;\n* Having engaged in \"chemsex\" in the past 12 months (defined as using CAD, including crystal methamphetamine, mephedrone, GBL\u002FGHB, and\u002For ecstasy\u002FMDMA)\n* Own a smartphone\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Enrolled in drug rehabilitation, substance use treatment, and narcotics or other behavioral intervention-based treatment\n* Unable to read and understand English or Bahasa Malaysia","MALE",{"count":155,"type":20},482,[62],"Chemsex, the use of psychoactive drugs before or during sexual activity, is a growing public health concern associated with striking increases in HIV, particularly among men who have sex with men (MSM). This study proposes to optimize an app-based just-in-time adaptive intervention, called JomCare, which aims to reduce chemsex risk by delivering tailored support when a person is most likely to be vulnerable to chemsex risk behaviors and receptive to intervention, with the purpose of reducing risk and averting new HIV infections.",[30,159],"Substance Abuse Disorder",[30,161,162,163],"mHealth","JITAI","Chemsex","2026-02-20",{"date":166,"type":40},"2026-02-23",{"date":168,"type":20},"2026-04-01",{"date":170,"type":20},"2029-05-30",{"name":46,"class":47},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":57,"sex":179,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":48},"100621045","phase-1-blackcurrants-modify-gut-microbiota-and-reduce-osteoporosis-risk-in-postmenopausal-females-100621045","NCT07365514","Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females","Blackcurrants Mitigate Postmenopausal Bone Loss Through Gut Microbiota-Bone Axis: A Randomized Clinical Trial Coupled With a Multi-Omics Approach to Inform Precision Nutrition","Inclusion Criteria:\n\n* postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years\n* not on hormone replacement therapy for at least one year before initiation of the study\n* maintaining normal exercise level (\\\u003C 7 hours\u002Fweek) and willing to avoid exercise for 24 hours prior to blood and stool sampling\n* willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg\u002Fday, three 392mg capsules)\n* willing to avoid other dietary supplements for the duration of the study\n* willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli\n* willing to have three blood draws, three stool collections, and three bone scans\n\nExclusion Criteria:\n\n* history of cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes mellitus, arthritis, or other chronic inflammatory diseases\n* current smokers\n* taking prescription medications known to alter bone and calcium metabolism\n* taking anabolic agents such as parathyroid hormone or growth hormone, or steroid within 3 months before the start of the study\n* taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder\n* alcohol consumption exceeding 2 drinks\u002Fday (approximately 14g of ethanol per drink) or a total of 12\u002Fweek\n* those with planned surgery during the study period or within 2 weeks of ending the intervention\n* those with sensitivities or allergies to any of the ingredients for the placebo (rice powder)\n* planning a procedure that includes iodine, barium or nuclear medicine isotopes within the study period\n* UConn students and\u002For employees who any key personnel teach or who report to any key personnel\n* study key personnel, partners of key personnel, or dependents\u002Frelatives of any key personnel","FEMALE","45 Years","70 Years",{"count":183,"type":20},159,[185],"PHASE1","The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.",[188,189,190],"Postmenopausal Osteoporosis","Gut Microbiome","Menopause",[192,193,194,195,196,197],"blackcurrant","gut microbiome","osteoporosis","menopause","females","bone aging","2026-01-25",{"date":200,"type":40},"2026-01-27",{"date":202,"type":20},"2026-02-01",{"date":204,"type":20},"2029-09",{"name":46,"class":47},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":48},"100493112","early-phase-1-evaluation-of-milk-polar-lipids-in-dyslipidemic-adults-with-abdominal-obesity-100493112","NCT05700916","Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity","Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity","Inclusion Criteria:\n\n* LDL-C ≥ 130 mg\u002FdL\n* Waist circumference ≥ 88 cm for women, ≥ 102 cm for men\n* Aged 18 to 70 years\n\nExclusion Criteria:\n\n* Renal disease\n* Liver disease\n* Diabetes\n* Heart disease\n* Stroke\n* Cancer\n* Eating disorders\n* Thyroid disease\n* Gut-associated pathologies\n* Autoimmune diseases\n* Chronic inflammatory diseases\n* Scleroderma\n* Gallbladder disease\n* Blood clotting disorders\n* Intravenous drug use\n* Fasting plasma\u002Fserum triglycerides \\>500 mg\u002FdL\n* Fasting plasma\u002Fserum glucose \\>126 mg\u002Fd\n* Weight changes \\>10% over last 4 weeks\n* Oral antibiotics use up to 1 month prior to and during study\n* Allergy or intolerance to milk products\n* Taking lipid-lowering medications (e.g., statins, fibrates)\n* Taking anti-inflammatory medications (e.g., corticosteroids)\n* Taking medications which primarily affect blood clotting (e.g., warfarin).",{"count":214,"type":20},130,[90],"The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.",[218,124],"Dyslipidemias","2025-12-15",{"date":221,"type":40},"2025-12-22",{"date":223,"type":40},"2023-10-20",{"date":225,"type":20},"2026-06",{"name":46,"class":47},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":48},"100545439","objective-integrated-multimodal-electrophysiological-index-for-the-quantification-of-visceral-pain-100545439","NCT06381921","Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain","OIME - Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain","OIME","Inclusion Criteria:\n\n* Participants need to be diagnosed with IBS by a healthcare provider according to Rome-III or -IV criteria, with a current report of abdominal pain.\n* Men and women 18-50 years old\n* Able to read and speak English\n* Daily access to a computer with internet access.\n\nExclusion Criteria:\n\n* Other chronic pains that are usually not comorbid with IBS, e.g., diabetic neuropathy, myofascial pain, low back pain, peripheral neuropathy etc.\n* Celiac disease or inflammatory bowel disease\n* Diabetes mellitus; d) Serious mental health conditions\n* Women during pregnancy or within 3 months post-partum period\n* Self- reported Regular use of opioids or other illicit substances.\n* Participants who have had COVID-19 should be fully recovered, and will be asked if their medical provider has made any restriction on activities.",{"count":236,"type":20},120,[62],"The objectives of the study are to 1) Conduct telemetric biosignals (EDA, ECG, and EMG) recording in healthy controls and IBS participants experiencing cutaneous and visceral pain; and 2) Validate the OIME index as a biomarker for quantifying pain in IBS participants and its capability to assess the treatment of IBS pain via an ambulatory trial.",[240],"Abdominal Pain",[242,243,244,245,246],"visceral pain","irritable bowel syndrome","autonomic and muscular activities","biosignals","personalized pain self-management","2025-09-08",{"date":249,"type":40},"2025-09-15",{"date":247,"type":40},{"date":252,"type":20},"2029-02-28",{"name":46,"class":47},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100406814","hiv-treatment-adherence-dose-determination-trial-100406814","NCT04577313","HIV Treatment Adherence Dose Determination Trial","DOSE DETERMINATION TRIAL: The Start\u002FPersist Studies","Inclusion Criteria:\n\n* Confirmed HIV positive\n* Confirmed prescribed antiretroviral therapy\n* Confirmed non-adherent to anti-retroviral therapy\n\nExclusion Criteria:\n\n* Does not have access to a phone\n* Does not have access to the internet",{"count":262,"type":20},400,[62],"The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.",[266],"HIV Infections","2025-08-22",{"date":269,"type":40},"2025-08-29",{"date":271,"type":40},"2020-09-01",{"date":273,"type":20},"2026-11-30",{"name":46,"class":47},2,{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":48},"100513688","assessment-of-gait-adaptation-due-to-an-asymmetric-walking-protocol-100513688","NCT05968729","Assessment of Gait Adaptation Due to an Asymmetric Walking Protocol","Inclusion Criteria:\n\n1. Able to read and speak English\n2. Age 18 - 30 years old\n3. Undergone ACLR surgery at the UConn Musculoskeletal Institute\n4. Must not have any concomitant surgeries or injuries\n5. Must be cleared to return-to-sport by a physician after they have completed rehabilitation\n6. Must be within 1 month of having been cleared for return-to-sport\n7. Must present with between-limb gait differences in load rate greater than 10%\n\nExclusion Criteria:\n\n1. Participants who have any recent inflammation, bleeding disorders, active bleeding, or infection within the lower limbs.\n2. History of injuries to their patellar tendon\n3. Cannot walk for extended periods of time\n4. Cannot have had any back and\u002For lower extremity injury that affects their ability to move.\n5. Cannot have difficulty or pain with walking, raising your arms, jogging, or jumping\n6. Must not be allergic to tape.","30 Years",{"count":284,"type":20},40,[62],"The purpose of this work is to conduct a comparative research-focused study to evaluate the effectiveness of how purposefully induced asymmetric walking protocols restore healthy, symmetric limb loading in individuals following post-anterior cruciate ligament reconstruction (ACLR) surgery. Additionally, computational modeling and machine learning to model knee loading in the clinic to determine the optimal asymmetric walking protocol to restore healthy gait in post-ACLR individuals.",[288],"Anterior Cruciate Ligament Reconstruction","2025-08-20",{"date":291,"type":40},"2025-08-27",{"date":293,"type":40},"2022-09-01",{"date":295,"type":20},"2027-07-31",{"name":46,"class":47},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":57,"sex":16,"minAge":86,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":21,"phases":306,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":321,"locationsCount":48},"100599091","effects-of-freeze-dried-grape-powder-on-immune-profiles-in-healthy-aging-adults-100599091","NCT07079982","Effects of Freeze-dried Grape Powder on Immune Profiles in Healthy Aging Adults","Inclusion Criteria:\n\n* 50-75 years old (at time of screening)\n* Body mass index (BMI) 18.5 to \\\u003C 30 kg\u002Fm2\n* Willing to consume grape and control powder during study periods, and refrain from eating grapes and certain other polyphenol-rich foods and beverages during the study\n* Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n* \\\u003C50 years old and \\>75 years old\n* BMI \\\u003C18.5 and ≥ 30 kg\u002Fm2 or body weight \\\u003C 110 pounds\n* Experienced \\>10% weight change in the past 4 weeks\n* Elevated fasting glucose levels (fasting glucose higher than 126 mg\u002FdL) and triglycerides greater than 500 mg\u002FdL\n* Self-reported and\u002For physician-diagnosed history of diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and\u002For relapsing\u002Fremitting autoimmune, inflammatory, or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation\n* Allergy to grapes or any ingredients in the grape or control powders\n* Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedance\n* Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics in the last 3 months, active use of probiotics during the intervention\n* Active smoker","75 Years",{"count":305,"type":20},28,[62],"The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults.\n\nThe main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant\u002Fgrape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.",[309,310],"Healthy Aging","Inflammation",[312,313,310,314],"Grapes","Healthy aging","Immune profiles","2025-07-25",{"date":317,"type":40},"2025-07-28",{"date":315,"type":40},{"date":320,"type":20},"2027-09",{"name":46,"class":47},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":48},"100586186","early-phase-1-l-acidophilus-strain-tw01-on-gut-health-body-composition-and-inflammation-100586186","NCT06912100","L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation","A Pilot Study of the Probiotic L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation","Inclusion Criteria:\n\n1. Age 18-60 years\n2. Body mass index (BMI) between 28 kg\u002Fm2 and 40 kg\u002Fm2\n3. Waist circumference ≥ 88 cm or 35 inches for women, ≥ 102 cm or 40 inches for men\n4. Willing to consume experimental capsules daily\n5. Willing to prepare and consume the delivered meal kits\n6. Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n1. Self-reported history of immunodeficiency, major gastrointestinal surgery, renal or liver disease, diabetes, heart disease, stroke, peripheral artery\u002Fvascular disease, cancer, eating disorders, gut-associated pathologies, autoimmune diseases, pacemaker, thyroid disease, gallbladder disease, chronic inflammatory diseases, scleroderma, blood clotting disorders, intravenous drug use\n2. Weight changes \\> 10% over the last 4 weeks\n3. Oral antibiotics and\u002For probiotics use up to 1 month prior to study and during study\n4. Currently taking GLP-1 analogues (e.g., Ozempic), anti-inflammatory medications (e.g., corticosteroids), daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) (occasional use is permitted), medications which primarily affect blood clotting (e.g., warfarin), or any medications that suppress the immune system.\n5. Dairy allergy\n6. Currently pregnant or breast-feeding",{"count":330,"type":20},12,[90],"This is a pilot research study to investigate the effects of a probiotic supplement (L. acidophilus, strain TW01) on substances found in the stool and bloodstream, gut bacteria composition, body composition, as well as any relationship of these substances with markers of inflammation. Lactobacillus acidophilus is commonly found in a variety of fermented foods, including yogurt, cheese, and kefir, due to its ability to produce lactic acid and other substances. This bacterium is generally well-tolerated in healthy individuals and has a longstanding history of safe use. The investigators are doing this pilot study to see if a particular probiotic, called L. acidophilus (strain TW01) and isolated from fermented coffee grounds, can make a positive difference in human gut and overall health. Specifically, the investigators want to look at how this probiotic affects certain substances in human stool and blood, the makeup of the bacteria in the gut, and aspects of body composition. The investigators are also interested in whether these changes relate to markers of inflammation, which can tell us more about their impact on overall health. This probiotic strain has been shown in other studies to be safe and well tolerated, and the investigators hope our research will help us better understand how it works and whether it might support health in humans.",[334,335],"Overweight (BMI > 25)","Obese, Otherwise Healthy Volunteers",[337,338,339],"obesity","probiotics","gut health","2025-07-22",{"date":315,"type":40},{"date":343,"type":40},"2025-07-01",{"date":345,"type":20},"2027-12",{"name":46,"class":47},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":354,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":48},"100560582","a-novel-program-using-ride-on-toys-to-improve-upper-extremity-function-in-children-with-hemiplegia-100560582","NCT06579027","A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia","A Novel, Child-friendly, Home-based Navigation Training Program Using Joystick-operated Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia: A Pilot Study","Inclusion Criteria:\n\n* Boys and girls between the ages of 3 - 8 years\n* Diagnosed with hemiplegia by a medical doctor with clear asymmetry in upper extremity strength and control (i.e., one upper limb is clearly weaker than the other)\n* Can maintain a supported sitting position for at least 15 minutes\n\nExclusion Criteria:\n\n* Only lower limb involvement\n* Recent history (within past 6 months) of trauma or surgery or Botox\n* Uncorrected blindness\u002Fprofound visual impairment\n* Fixed deformities at wrist or hand\n* No active control in affected UE\n* Inability to follow 2-step directions\n* Weight \\> 150 lbs.","3 Years","8 Years",{"count":357,"type":20},30,[62],"The purpose of this study is to assess the feasibility and utility of 2 types of play-based training programs co-delivered by researchers and caregivers within home\u002Fcommunity settings to promote arm function among 3-to-8-year-old children with hemiplegia. Specifically, investigators will assess the feasibility of implementation and acceptance\u002Fsatisfaction associated with a researcher-caregiver co-delivered community-based training program involving either joystick-operated powered ride-on toys (SPEED training) or creative upper extremity training (CRAFT training).\n\nThe investigators will also compare the effects of these 2 types of training programs on children's arm motor function and spontaneous use of their affected arm during daily activities.",[361,362,363],"Hemiplegia","Cerebral Palsy","Children, Only","2025-06-04",{"date":366,"type":40},"2025-06-05",{"date":368,"type":40},"2024-09-26",{"date":370,"type":20},"2026-09-01",{"name":46,"class":47},""]